Foreword by J. Michael Maloney
In this supplement to the American Journal of Clinical Dermatology the use of
the combined oral contraceptive (OC) ethinylestradiol/chlormadinone acetate
(EE/CMA) 0.03mg/2mg in female patients with commonly seen disorders of the
pilosebaceous unit (PSU): acne, female pattern hair loss (FPHL), hirsutism and
seborrhea is discussed. These dermatological disorders share the features of being
caused by hyperactivity of androgen within the pilosebaceous follicle, and al-
though not life threatening are the source of a considerable psychological and
emotional burden for patients. Approved in Europe as a contraceptive, EE/CMA
0.03mg/2mg is also currently being evaluated as a treatment for acne. Some data
also exist suggesting that EE/CMA may have a beneficial effect in patients with
FPHL, hirsutism and seborrhea.
Understanding the scientific basis of these conditions allows clinicians to predict
thatEE/CMAwouldbehelpful in the treatment of disorders of thePSU.DrsGuerra-
Tapia and Sancho Pe´rez from the Department of Dermatology and the Department
of Gynecology and Obstetrics in Complutense University, Madrid, Spain, offer a
comprehesive snapshot of the physiological and pharmacological mechanisms that
act as the foundation of the pathophysiology of these conditions. Their ‘state of the
science’ review reveals what we know about these diseases and also highlights the
large gaps remaining in our understanding of these troubling conditions.
Implied by the cooperative effort of Drs Guerra-Tapia and Sancho Pe´rez is the
fact that the best care of the female patient with disorders of the PSU often
requires close cooperation between her dermatologist and her gynaecologist. As
pointed out in the review, there are female patients who have elevated circulating
androgen levels but do not manifest evidence of PSU disorders. Contrawise other
patients have normal circulating androgens but still present with disorders of the
PSU. Adequate work-up requires ruling out inherited disorders, congenital ab-
normalities and neoplasms as well as other endocrine disorders not treated simply
with OC. As noted by Drs Guerra-Tapia and Sancho Pe´rez, the conversion of
testosterone to dihydrotestosterone by 5a-reductase is the important step in the
pathophysiology of these diseases of the PSU. The enzyme 5a-reductase remains
an elusive target for effective pharmacological intervention.
By some estimates, acne occurs in up to 50% of women in their childbearing
years and is thus the most common of the disorders of the PSU discussed in this
supplement. Its frequency in the population of patients taking OC makes it a
much easier disease to study than the other disorders it shares pathophysiology
with. Combined OC of the oestrogen/progestin type may diminish the androgen
effect on the PSU by decreasing androgen production in the ovary and adrenal as
well as by blocking the interaction of androgens at the PSU. Comparative studies
have been published documenting the effectiveness of EE/CMA in acne patients.
Drs Guerra-Tapia and Sancho Pe´rez used a comprehensive literature search to
identify and review studies designed to document the effectiveness of EE/CMA in
FPHL, hirsutism and seborrhea. Unfortunately, no comparative studies were
found. However, as pointed out in the review within this supplement, there were
subgroups of patients in various studies with FPHL, hirsutism and seborrhea.
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A review of the data from these subgroups suggests EE/CMAwould be helpful in
treating these patients.
Many practitioners claim to prefer to practice ‘evidence-based medicine’ but
are confronted daily by the dilemma of not having adequate information available
to guide their clinical decisions. Although not considered ‘top-level evidence’ from
a purely scientific viewpoint, case reports serve a distinct purpose. The clinician
who is presented with a patient having a unique set of symptoms for which a
double-blind, placebo-controlled trial is not available often needs some help to fill
in the gaps of knowledge and give him or herself confidence to try a new treatment.
As a primary care dermatologistmyself I am aware that knowing that the therapeutic
option under consideration has been helpful to at least one other physician–patient
duo previously can be reassuring.
We are fortunate then to have available in this supplement a series of four case
reports compiled by Mercedes Go´mez Va´zquez, Ramo´n Navarra Amayuelas,
Marta Lamarca, Laura Baquedano, Sebastia´n Romero Ruiz, Eduardo Vilar-
Checa andMaria D. Iniesta. Having already been presented with the ‘state of the
science’ these case reports can be thought of as a ‘state of the art’ review. These
case reports give the dermatologist a feel as to howEE/CMAcan be used in similar
patients they may see in their own practices. As the reader will note, disorders
of the PSU often occur in clusters and may be associated with other non-
dermatological conditions such as irregular menstruation, anovulation and poly-
cystic ovarian disorder. A common theme in the case reports is that several
menstrual cycles are sometimes needed for EE/CMA to produce optimal results in
the concomitant PSU disorder.
Of particular interest in these case reports is the careful testing, imaging and
examination used by these experienced practitioners to rule out other systemic
causes of a PSU disorder. Dermatologists who are not willing to provide similar
work-up should consider referring their patient out for these tests before starting
the patient on OC.
The dermatologist in theUSA is often confrontedwith a disease or constellation
of symptoms for which there is not a drug that is US Food and Drug Adminis-
tration approved. While there are many qualities that describe a good clinician,
finding a safe and creative therapeutic option to improve a particular patient’s
condition is tome one of themost important. It is good to remember thatEE/CMA
is not available in the USA at this time, is not yet approved for the treatment of
acne in patients seeking contraception, and probably will never receive regulatory
approval for the less common disorders of hirsutism, FPHL and seborrhea.
OC are usually well tolerated but like any drug have potential side-effects and
risks. In female patients who desire contraception and who also have a disorder of
the PSU, using EE/CMA as the choice of contraception may be a good option.
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